Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director · Chief Executive Officer | September 17, 2026 | September 21, 2026 |
| Eidos Therapeutics, Inc.EIDX · Entity 143355 | Director · Chief Executive Officer · 10% owner | July 03, 2019 | July 09, 2019 |
| LianBioLIAN · Entity 9881 | Director | October 29, 2021 | November 09, 2021 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | March 27, 2026 | March 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
BridgeBio Pharma, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. | 495,686 |
Last balance in matching sequence
After 2026-09-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-17 · Sale · Disposed 8,721 · Balance 496,965 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Row 2 · 2026-09-17 · Sale · Disposed 1,279 · Balance 495,686 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. | 3,568,447 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,568,447 F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy NK 2026 GRAT | 750,000 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 750,000 F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 243,327 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 243,327 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026.
F2: Represents the weighted average sale price of the shares sold from $68.52 to $69.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F4: Represents the weighted average sale price of the shares sold from $69.525 to $69.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: These shares are held by the NK 2026 GRAT, a grantor retained annuity trust of which the Reporting Person is the sole trustee and sole annuitant. The Reporting Person disclaims beneficial ownership of the shares held by the NK 2026 GRAT except to the extent of his pecuniary interest therein.
Eidos Therapeutics, Inc.
Report date July 03, 2019 · Filed July 09, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 24,575,501 |
Reported balance
After 2019-07-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-07-03 · Purchase · Acquired 882,353 · Balance 24,575,501 F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.
LianBio
Report date October 29, 2021 · Filed November 09, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy BridgeBio Pharma LLC | 5,002,792 |
Reported balance
Holding disclosure · report date 2021-10-29 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 5,002,792 F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are held by BridgeBio Pharma LLC, a wholly-owned subsidiary of BridgeBio Pharma, Inc. Dr. Neil Kumar is the President and Chief Executive Officer and a director of BridgeBio Pharma, Inc., and as a result may be deemed to share voting and investing power over these Ordinary Shares. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Maze Therapeutics, Inc.
Report date March 27, 2026 · Filed March 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.38 · Expires 2036-03-26 | Direct | 33,417 |
Reported balance
After 2026-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-27 · Grant · Acquired 33,417 · Balance 33,417 F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/36th of the total award monthly, with the first tranche vesting on April 27, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 3,085 | $8.84 | $27,271.40 |
DisclosureSEC source: 0000899243-22-007031 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,727,243 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 7,524 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 7,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-007031 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,730,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 23:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 786,072 | $0.00 Strike: $38.62 | $0.00 |
DisclosureSEC source: 0000899243-21-047188 · doc4.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,072 Underlying: Common Stock · 786,072 shares Expires 2031-12-02 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 2,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045260 · doc4.xml · derivative · entry 6 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,124 Underlying: Common Stock · 2,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045260 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,294 Underlying: Common Stock · 5,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 3,730 | $47.25 | $176,242.50 |
DisclosureSEC source: 0000899243-21-045260 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,722,804 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 7,523 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 21:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 7,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-045260 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 2,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033438 · doc4.xml · derivative · entry 6 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,518 Underlying: Common Stock · 2,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-033438 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,423 Underlying: Common Stock · 5,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 3,730 | $49.48 | $184,560.40 |
DisclosureSEC source: 0000899243-21-033438 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,719,011 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 7,523 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 7,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-033438 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,722,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 2,394 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019799 · doc4.xml · derivative · entry 6 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,912 Underlying: Common Stock · 2,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019799 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,552 Underlying: Common Stock · 5,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 3,731 | $53.66 | $200,205.46 |
DisclosureSEC source: 0000899243-21-019799 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,715,218 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 7,524 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2021 Filed May 18, 2021 22:29 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 7,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-019799 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,718,949 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 00:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 16,000 | $62.50 | $1,000,000.00 |
DisclosureSEC source: 0000899243-21-007211 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,711,425 Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007211 · doc4.xml · derivative · entry 6 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,682 Underlying: Common Stock · 5,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 2,139 | $64.98 | $138,992.22 |
DisclosureSEC source: 0000899243-21-007211 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,695,425 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 5,129 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 5,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-007211 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,697,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 38,306 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006432 · doc4.xml · derivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,306 Underlying: Common Stock · 38,306 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The units will vest in 16 equal quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F3 · derivative.expiration_date: The units will vest in 16 equal quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 01:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 225,971 | $0.00 Strike: $68.87 | $0.00 |
DisclosureSEC source: 0000899243-21-006432 · doc4.xml · derivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,971 Underlying: Common Stock · 225,971 shares Expires 2031-02-09 F1 · derivative.exercise_date: The option will vest in 48 equal month installments after February 10, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 24, 2020 Filed Feb 12, 2021 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GiftCommon Stock | 268,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006293 · doc5.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,195,686 F2 · ownership.nature: The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| November 24, 2020 Filed Feb 12, 2021 21:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GiftCommon Stock | 472,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006293 · doc5.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,612,722 F1 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031571 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,811 Underlying: Common Stock · 5,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F5 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and November 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,774 | $44.33 | $78,641.42 |
DisclosureSEC source: 0000899243-20-031571 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,692,435 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,129 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:51 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 5,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-031571 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,694,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 5,129 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-022791 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,940 Underlying: Common Stock · 5,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. F5 · derivative.expiration_date: The RSUs vest over approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. 6.25% of the RSUs vested on August 16, 2020 and an additional 6.25% will vest in quarterly installments on the 16th day of each February, May, August and November thereafter, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,774 | $28.53 | $50,612.22 |
DisclosureSEC source: 0000899243-20-022791 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,689,080 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 5,129 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 23:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 5,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022791 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 22:47 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 6,759 | $27.36 | $184,914.07 |
DisclosureSEC source: 0000899243-20-021550 · doc4.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,085,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $27.16 to $27.59 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 04, 2020 Filed Aug 5, 2020 22:47 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 7,184 | $26.70 | $191,845.85 |
DisclosureSEC source: 0000899243-20-021550 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,092,131 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $26.16 to $27.15 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:47 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 3,040 | $28.12 | $85,498.18 |
DisclosureSEC source: 0000899243-20-021550 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,099,315 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $27.78 to $28.57 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 22:47 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 63,017 | $27.23 | $1,715,807.97 |
DisclosureSEC source: 0000899243-20-021550 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,102,355 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $26.77 to $27.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2, 4, 5 and 6. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 23:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 56,445 | $30.22 | $1,706,021.90 |
DisclosureSEC source: 0000899243-20-018518 · doc4.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,165,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.78 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 23:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,700 | $32.42 | $87,520.50 |
DisclosureSEC source: 0000899243-20-018518 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,221,817 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $32.16 to $32.74 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 23:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 33,700 | $31.67 | $1,067,343.03 |
DisclosureSEC source: 0000899243-20-018518 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,224,517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $31.15 to $32.14 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| July 01, 2020 Filed Jul 6, 2020 23:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 50,625 | $30.63 | $1,550,471.63 |
DisclosureSEC source: 0000899243-20-018518 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,258,217 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.13 to $31.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2, 4, 5 and 6. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 10,600 | $30.01 | $318,125.08 |
DisclosureSEC source: 0000899243-20-015953 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,308,842 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.08 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 82,069 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-015534 · doc4.xml · derivative · entry 5 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,069 Underlying: Common Stock · 82,069 shares Expires not disclosed F6 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. F7 · derivative.expiration_date: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 590,551 | $0.00 Strike: $28.86 | $0.00 |
DisclosureSEC source: 0000899243-20-015534 · doc4.xml · derivative · entry 4 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,551 Underlying: Common Stock · 590,551 shares Expires 2030-06-02 F5 · derivative.exercise_date: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 23:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,930 | $30.05 | $178,173.37 |
DisclosureSEC source: 0000899243-20-015534 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,319,442 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.00 to $30.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 8,709 | $29.71 | $258,711.30 |
DisclosureSEC source: 0000899243-20-015045 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,325,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $29.60 to $29.965 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 71,291 | $29.13 | $2,076,678.31 |
DisclosureSEC source: 0000899243-20-015045 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,334,081 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.60 to $29.59 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 34,834 | $31.23 | $1,088,012.12 |
DisclosureSEC source: 0000899243-20-012192 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,405,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $31.12 to $31.55 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 05, 2020 Filed May 7, 2020 00:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 44,766 | $30.86 | $1,381,469.81 |
DisclosureSEC source: 0000899243-20-012192 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,440,206 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $30.12 to $31.115 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 4. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 33,974 | $29.77 | $1,011,494.31 |
DisclosureSEC source: 0000899243-20-012046 · doc4.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,484,972 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $29.49 to $30.14 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 5,706 | $29.13 | $166,190.67 |
DisclosureSEC source: 0000899243-20-012046 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,518,946 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $28.48 to $29.47 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 4,098 | $29.78 | $122,054.83 |
DisclosureSEC source: 0000899243-20-012046 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,524,652 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $29.62 to $30.14 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 36,622 | $29.06 | $1,064,345.19 |
DisclosureSEC source: 0000899243-20-012046 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,528,750 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $28.62 to $29.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| April 07, 2020 Filed Apr 9, 2020 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,805 | $25.48 | $45,983.10 |
DisclosureSEC source: 0000899243-20-010587 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,565,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $25.24 to $25.76 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.